Fas/FasL interaction: A novel immune therapy approach with immobilized biologicals

Medicinal Research Reviews

Volumn 25, Issue 3, 2005, Pages 331-342

  Scholz, Martin ^a   Cinatl, Jindrich ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Immune management; Novel therapeutic strategies

Indexed keywords

FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; IMMOBILIZED ANTIBODY;

DEVICE; EXTRACORPOREAL CIRCULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INHIBITION KINETICS; LEUKOCYTE ACTIVATION; NONHUMAN; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SWINE; SYSTEMIC THERAPY; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; CARDIOPULMONARY BYPASS; EQUIPMENT AND SUPPLIES; FAS LIGAND PROTEIN; HUMANS; IMMUNOGLOBULIN M; INTERLEUKIN-8; LYMPHOMA, T-CELL; MEMBRANE GLYCOPROTEINS; VIRUS DISEASES;

EID: 16844363920     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20025     Document Type: Review

References (68)

1. Gulbins E, Jekle A, Ferlinz K, Grassme H, Lang F. Physiology of apoptosis. Am J Physiol Renal Physiol 2000;279:F605-F615.
2. Dockrell DH. The multiple roles of Fas ligand in the pathogenesis of infectious diseases. Clin Microbiol Infect 2003;9:766-779.
3. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A. Anticancer drugs of tomorrow: Apoptotic pathways as targets for drug design. Drug Discov Today 2003;8:67-77.
4. Everett H, McFadden G. Apoptosis: An innate immune response to virus infection. Trends Microbiol 1999;7:160-165.
5. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317.
6. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-976.
7. Scheel-Toellner D, Wang K, Craddock R, Webb PR, McGettrick HM, Assi LK, Parkes N, Clough LE, Gulbins E, Salmon M, Lord JM. Reactive oxygen species limit neutrophil lifespan by activating Death Receptor Signaling. Blood 2004. Epub 2004 Jul 06.
8. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8:504-512.
9. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
10. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, Kaneko Y, Hara N. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997;17:272-278.
11. Scholz M, Simon A, Berg M, Schuller AM, Hacibayramoglu M, Margraf S, Theisen A, Windolf J, Wimmer-Greinecker G, Moritz A. In vivo inhibition of neutrophil activity by a FAS (CD95) stimulating module: Arterial in-line application in a porcine cardiac surgery model. J Thorac Cardiovasc Surg 2004;127:1735-1742.
12. Moreno JB, Margraf S, Schuller AM, Simon A, Moritz A, Scholz M. Inhibition of neutrophil activity in cardiac surgery with cardiopulmonary bypass: A novel strategy with the leukocyte inhibition module. Perfusion 2004;19:11-16.
13. Cinatl J, Jr., Blaheta R, Bittoova M, Scholz M, Margraf S, Vogel JU, Cinatl J, Doerr HW. Decreased neutrophil adhesion to human cytomegalovirus- infected retinal pigment epithelial cells is mediated by virus-induced up-regulation of Fas ligand independent of neutrophil apoptosis. J Immunol 2000;165: 4405-4413.
14. Greenstein S, Barnard J, Zhou K, Fong M, Hendey B. Fas activation reduces neutrophil adhesion to endothelial cells. J Leukoc Biol 2000;68:715-722.
15. Sieg S, Smith D, Kaplan D. Differential activity of soluble versus cellular Fas ligand: Regulation by an accessory molecule. Cell Immunol 1999;195:89-95.
16. Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14:53-66.
17. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
18. Tang M, Gu YJ, Wang WJ, Xu YP, Chen CZ. Effect of cardiopulmonary bypass on leukocyte activation: Changes in membrane-bound elastase on neutrophils. Perfusion 2004;19:93-99.
19. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-305.
20. Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S. Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc Natl Acad Sci USA 1990;87:9620-9624.
21. Cox G, Crossley J, Xing Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary inflammation in vivo. Am J Respir Cell Mol Biol 1995;12:232-237.
22. Stegmayr BG. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Ther Apher 2001;5:123-127.
23. Stuber F, Wrigge H, Schroeder S, Wetegrove S, Zinserling J, Hoeft A, Putensen C. Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Med 2002;28:834-841. Epub 2002 Jun 15.
24. Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F. Bench-to-bedside review: beta2-agonists and the acute respiratory distress syndrome. Crit Care 2004;8:25-32. Epub 2003 Dec 23.
25. Chaney MA: Corticosteroids and cardiopulmonary bypass. A review of clinical investigations. Chest 2002;121:921-931.
26. Hamamoto M, Suga M, Nakatani T, Takahashi Y, Sato Y, Inamori S, Yagihara T, Kitamura S: Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model. Eur J Cardio Thorac Surg 2004;25:833-838.
27. Sato Y, Sato S, Yamamoto T, Ishikawa S, Onizuka M, Sakakibara Y. Phosphodiesterase 4 inhibitor reduces the retention of polymorphonuclear leukocytes in the lung. Am J Physiol Lung Cell Mol Physiol 2002;282:L1376-L1381.
28. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
29. Lu YY, Koga Y, Tanaka K, Sasaki M, Kimura G, Nomoto K. Apoptosis induced in CD4+ cells expressing gp160 of human immunodeficiency virus type 1. J Virol 1994;68:390-399.
30. Biswas P, Poli G, Orenstein JM, Fauci AS. Cytokine-mediated induction of human immunodeficiency virus (HIV) expression and cell death in chronically infected U1 cells: Do tumor necrosis factor alpha and gamma interferon selectively kill HIV-infected cells? J Virol 1994;68:2598-2604.
31. Srivastava MD, Srivastava BI. Soluble Fas and soluble Fas ligand proteins in human milk: Possible significance in the development of immunological tolerance. Scand J Immunol 1999;49:51-54.
32. Prösch S, Cinatl J, Scholz M, editors. CMV-related immunopathology II. Monographs in virology. Basel: Karger Verlag; 2003. ISBN 3-8055-7618-8.
33. Zhang HG, Fleck M, Kern ER, Liu D, Wang Y, Hsu HC, Yang P, Wang Z, Curiel DT, Zhou T, Mountz JD. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest 2000;105:813-821.
34. Greil R, Anether G, Johrer K, Tinhofer I. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: Pathways, targets, and therapeutic tools. J Leukoc Biol 2003;74:311-330.
35. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative syndrome. Ann Intern Med 1999;130:591-601.
36. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, Peters AM, Sneller MC, Hallahan CW, Wang J, Fischer RE, Jackson CM, Lin AY, Baumler C, Siegert E, Marx A, Vaishnaw AK, Grodzicky T, Fleisher TA, Lenardo MJ. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98:194-200.
37. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street. Blood 1997;90:1952-1959.
38. Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 1998;91:3935-3942.
39. Gutierrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, Magrath I, Bhatia K. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 1999;59:696-703.
40. Koizumi T, Wang J, Suzuki Y, Masuda K, Watanabe T. Regulation of bcl-xL expression and Fas susceptibility in mouse B cells by CD40 ligation, surface IgM crosslinking and IL-4. Mol Immunol 1996;33:1247-1253.
41. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997;97:409-417.
42. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 2002;100:4108-4115. Epub 2002 Jul 25.
43. Handgretinger R, Leung W, Ihm K, Lang P, Klingebiel T, Niethammer D. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? Br J Cancer 2003;88:1874-1877.
44. Sheikh MS, Huang Y. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 2004;4:97-104.
45. Bosman FT, Visser BC, van Oeveren J. Apoptosis: Pathophysiology of programmed cell death. Pathol Res Pract 1996;192:676-683.
46. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946.
47. Prasad KV, Prabhakar BS. Apoptosis and autoimmune disorders. Autoimmunity 2003;36:323-330.
48. Matsuno H, Yudoh K, Nakazawa F, Sawai T, Uzuki M, Nishioka K, Yonehara S, Nakayama J, Ohtsuki M, Kimura T. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol 2002;29:1609-1614.
49. Ichikawa K, Yoshida-Kato H, Ohtsuki M, Ohsumi J, Yamaguchi J, Takahashi S, Tani Y, Watanabe M, Shiraishi A, Nishioka K, Yonehara S, Serizawa N. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000;12:555-562.
50. Kuwahara H, Tani Y, Ogawa Y, Takaichi Y, Shiraishi A, Ohtsuki M. Therapeutic effect of novel anti-human Fas antibody HFE7a on graft-versus-host disease model. Clin Immunol 2001;99:340-346.
51. Salmen S, Teran G, Borges L, Goncalves L, Albarran B, Urdaneta H, Montes H, Berrueta L. Increased Fas-mediated apoptosis in polymorphonuclear cells from HIV-infected patients. Clin Exp Immunol 2004;137:166-172.
52. Poppema S, Maggio E, van den Berg A. Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma 2004;45:423-431.
53. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003;21:S69-S77.
54. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104:13-19.
55. Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I. Delayed apoptosis of circulating neutrophils in Kawasaki disease. Clin Exp Immunol 2001;126:355-364.
56. Askenasy N, Yolcu ES, Wang Z, Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 2003;107:1525-1531.
57. Chou WH, Choi DS, Zhang H, Mu D, McMahon T, Kharazia VN, Lowell CA, Ferriero DM, Messing RO. Neutrophil protein kinase Cdelta as a mediator of stroke-reperfusion injury. J Clin Invest 2004;114:49-56.
58. Yang J, Jones SP, Suhara T, Greer JJ, Ware PD, Nguyen NP, Perlman H, Nelson DP, Lefer DJ, Walsh K. Endothelial cell overexpression of fas ligand attenuates ischemia-reperfusion injury in the heart. J Biol Chem 2003;278:15185-15191.
59. Okuda Y, Sakoda S, Fujimura H, Nagata S, Yanagihara T, Bernard CC. Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2000;275:164-168.
60. Mevorach D. Systemic lupus erythematosus and apoptosis: A question of balance. Clin Rev Allergy Immunol 2003;25:49-60.
61. Suzuki N, Ichino M, Mihara S, Kaneko S, Sakane T. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:344-353.
62. Manganelli P, Fietta P. Apoptosis and Sjogren syndrome. Semin Arthritis Rheum 2003;33:49-65.
63. Angele MK, Faist E. Clinical review: Immunodepression in the surgical patient and increased susceptibility to infection. Crit Care 2002;6:298-305. Epub 2002 May 24.
64. Jacobs P, Glorieux G, Vanholder R. Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis. Nephrol Dial Transplant 2004;19:V41-V45.
65. Oksuz M, Akkiz H, Isiksal YF, Saydaogluc G, Serin M, Kayaselcuk F, Abayli B, Tuncer I. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol 2004;16:341-345.
66. Sakamoto N, Mukae H, Fujii T, Kakugawa T, Kaida H, Kadota J, Kohno S. Soluble form of Fas and Fas ligand in serum and bronchoal veolar lavage fluid of individuals infected with human T-lymphotropic virus type 1. Respir Med 2004;98:213-319.
67. Aref S, Salama O, Al-Tonbary Y, Mansour A. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia. Hematology 2004;9:113-121.
68. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95-103.